MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 01-26-2023
Myovant Sciences Ltd. EBITDA per Share 2011-2026 | MYOV
Annual EBITDA per Share Myovant Sciences Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.89 | -3.18 | -3.95 | -2.37 | -1.13 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.13 | -3.95 | -2.7 |
Quarterly EBITDA per Share Myovant Sciences Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.98 | -0.44 | - | -0.64 | -1.45 | -0.81 | - | -0.87 | -0.87 | -0.8 | -0.38 | -0.88 | -0.96 | -0.79 | -0.88 | -1.04 | -1.04 | -0.98 | - | -0.7 | -0.51 | -0.37 | - | -0.15 | -1.34 | -1.29 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.04 | -1.45 | -0.781 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-0.71 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-0.82 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Coherus BioSciences
CHRS
|
-1.54 | $ 1.63 | -4.4 % | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
12.6 | - | - | $ 96.9 B |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-1.05 | $ 0.73 | -0.03 % | $ 33.4 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.67 | $ 7.83 | -5.21 % | $ 214 M | Israel |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
0.29 | $ 3.12 | - | $ 649 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-3.51 | - | 0.74 % | $ 768 M | Israel |
 |
Exelixis
EXEL
|
3.32 | $ 51.1 | -0.37 % | $ 13.9 B | USA |
|
Forte Biosciences
FBRX
|
-5.45 | $ 23.96 | -2.84 % | $ 310 M | USA |
|
Galera Therapeutics
GRTX
|
-0.03 | - | -32.59 % | $ 7.61 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
-8.27 K | $ 8.9 | 0.56 % | $ 1.08 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.67 | $ 4.4 | -7.76 % | $ 1.31 B | Canada |
 |
Midatech Pharma plc
MTP
|
-0.03 | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
3.68 | $ 17.3 | -5.57 % | $ 809 M | USA |
 |
BioNTech SE
BNTX
|
-5.81 | $ 91.99 | -0.26 % | $ 22.2 B | Germany |
 |
Compugen Ltd.
CGEN
|
-0.41 | $ 3.03 | 6.32 % | $ 283 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Gilead Sciences
GILD
|
8.35 | $ 132.06 | -0.74 % | $ 164 B | USA |
 |
Genmab A/S
GMAB
|
10.4 | $ 26.9 | 1.32 % | $ 1.74 B |  Danmark |
 |
Genprex
GNPX
|
-16.6 | $ 0.86 | 1.2 % | $ 802 K | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.49 | -4.12 % | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-3.37 | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
1.75 | $ 7.79 | 1.04 % | $ 5.29 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Fortress Biotech
FBIO
|
-2.5 | $ 2.3 | 3.14 % | $ 64.2 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 21.57 | -0.55 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-0.22 | $ 9.24 | 36.48 % | $ 264 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
0.15 | - | -11.43 % | $ 502 K | USA |